BACKGROUND: Lanadelumab is a plasma kallikrein inhibitor approved in many countries, including China, for the long-term prophylaxis of hereditary angioedema (HAE). The primary objective was safety evaluation of lanadelumab for HAE long-term prophylaxis in a Chinese patient population. Secondary objectives included efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity evaluations.
METHODS: This open-label, prospective, phase 3, post-approval commitment study included patients in China aged ≥12 years with HAE due to C1 inhibitor deficiency (HAE-C1INH) (NCT05460325). Eligible patients with ≥1 HAE attack in the 4-week run-in period received subcutaneous lanadelumab 300 mg every 2 weeks during days 0-182 for 14 doses in total.
RESULTS: Twenty patients were enrolled (median age, 38 years; 7 male), and all completed the study. No treatment-emergent adverse events (TEAEs) were fatal, led to treatment discontinuation, or were of special interest. Fifteen (75%) patients reported ≥1 TEAE during the study, most commonly COVID-19 infection (50%). Nine (45%) patients reported treatment-related TEAEs, most frequently injection site pain (20%) and swelling (15%). Injection site reactions occurred in 25% of patients. Mean ± SD monthly rate of investigator-confirmed attacks decreased by 99.1% during days 0-182 versus run-in (0.04 ± 0.14 vs 2.50 ± 1.44). Eighteen (90%) patients were attack free during days 0-182; 2 patients experienced a total of 4 mild and 1 moderate investigator-confirmed HAE attacks. Lanadelumab pharmacokinetics, pharmacodynamics, and immunogenicity in Chinese patients were consistent with other patient populations.
CONCLUSION: These findings in patients with HAE in China are consistent with the profile of lanadelumab established in patients from other regions, supporting its use as first-line long-term prophylaxis.
These findings in patients with HAE in China are consistent with the profile of lanadelumab established in patients from other regions, supporting its use as first-line long-term prophylaxis.
first-line positioning outruns the selected, uncontrolled 20-patient design despite consistency with established external evidence
Mean ± SD monthly rate of investigator-confirmed attacks decreased by 99.1% during days 0-182 versus run-in
directly reported pre/post reduction, though attack-enriched eligibility and no concurrent control limit attribution
No treatment-emergent adverse events (TEAEs) were fatal, led to treatment discontinuation, or were of special interest
directly observed safety outcomes in the completed 20-patient cohort, with limited precision for uncommon events
Lanadelumab pharmacokinetics, pharmacodynamics, and immunogenicity in Chinese patients were consistent with other patient populations
measured profiles align descriptively with historical populations, but the comparison is based on only 20 patients
Derived from the full evaluation — not a separate score.
Strengths
The study prospectively evaluates multiple dimensions of lanadelumab’s profile in Chinese patients, where the Introduction identifies prior evidence as limited mainly to small reports and a recent multicentre observational study.
↳ Introduction, final paragraph; Discussion, paragraph 1
Investigator-confirmed diary outcomes were accompanied by similar patient-reported sensitivity results and sustained suppression of the pharmacodynamic marker cHMWK. These measures support the direction of the observed treatment-period findings despite the uncontrolled design.
↳ Results, Efficacy; Supplementary Table 2; Results, Pharmacodynamics and Pharmacokinetics
The Discussion compares attack reductions and attack-free proportions with HELP, the Japanese phase 3 study, international real-world studies, and Chinese cohorts, including studies reporting smaller effects.
↳ Discussion, efficacy-comparison paragraphs
Limitations
Eligibility required attacks during a short run-in, after which all patients received open-label treatment. Without a concurrent control or quantitative bias analysis, regression to the mean and period effects remain plausible contributors to the observed reduction.
↳ Methods, Study Design and Treatment; Methods, Patients; Statistical Analysis
Only 20 patients were observed for approximately six months, including two severe treatment-related hepatic events. This sample cannot precisely characterize uncommon adverse events or subgroup differences.
↳ Results, Safety and Tolerability; Discussion, safety paragraphs and limitations paragraph
The conclusion states that the findings support first-line prophylaxis, although the study provides uncontrolled local corroboration rather than independent comparative evidence for treatment positioning.
↳ Abstract, Conclusion; Discussion, final paragraph
The study’s strongest contribution is prospective local confirmation across safety, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity in a Chinese population. Complete follow-up, investigator-confirmed diaries, similar patient-reported sensitivity results, and cHMWK suppression support the direction of the findings. The efficacy estimate nevertheless comes from an open-label pre/post comparison whose eligibility rules selected patients with recent attacks, leaving regression to the mean insufficiently addressed. The Discussion places the results within a substantial international and Chinese evidence base, but the first-line-use conclusion should be read as corroborative rather than independently established.
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
Sound3.5
Confidence mediumThe study provides prospective multicentre safety, efficacy, pharmacokinetic, pharmacodynamic, and immunogenicity data for a Chinese population previously represented mainly by smaller reports. The advance is clinically and regulatorily relevant but incremental because lanadelumab’s profile was already established internationally and emerging Chinese evidence was available.
“Published data on the outcomes of Chinese patients receiving lanadelumab are limited”
Prospective follow-up, daily diary recording, investigator confirmation, complete study completion, and a patient-reported sensitivity analysis support execution. The uncontrolled pre/post comparison and attack-based run-in eligibility leave regression-to-the-mean and temporal effects insufficiently addressed.
“To be eligible for the study, patients must have experienced ≥1 investigator-confirmed HAE attack within 4 weeks during the run-in period.”
The manuscript follows a coherent progression from the Chinese evidence gap through design, results, and comparison with prior studies, and generally uses consistency-based language. The concluding statement supporting first-line use is broader than this small uncontrolled study can establish independently.
“supporting its use as first-line long-term prophylaxis”
The Discussion quantitatively compares the findings with pivotal, Japanese, real-world, and Chinese studies and explicitly identifies sample size, open-label design, lack of control, and short follow-up. The implications of attack-enriched eligibility and regression to the mean are not fully integrated into the efficacy interpretation.
“This study is also limited by the open-label study design, lack of a control group, and short follow-up.”
Caveats4 of 4 checks
Participant flow, efficacy totals, exposure, and adverse-event descriptions are internally consistent, including the distinction between severe and serious events. The registration and study-start dates are themselves reported consistently, so their ordering is treated under research conduct rather than internal coherence.
Ethics approvals and informed consent are declared, but the reported study start preceded the stated registration date by approximately three weeks. No conflict-of-interest declaration appears in the supplied article text, while a conditional individual-participant-data availability process is provided.
Flags: 2 declared / 5 total
35 of 35 checkable references verified
38 references in manuscript 3 are books, websites or datasets — counted, but not index-checkable the reference list may be incompletely parsed; counts are indicative
References not verified automatically are resolved manually within 24 hours.
No retraction or expression of concern found in Crossref (includes Retraction Watch).
Sources: Crossref (incl. Retraction Watch) ✓
Where this paper’s evidence sits on the path from initial observation to real-world use.
This phase 3 post-approval commitment study evaluates an already approved treatment in the intended national population, placing it close to clinical use. Its small uncontrolled design limits its ability to independently guide comparative treatment choices or long-term safety decisions.
“a prospective, phase 3, post-approval commitment study”
AI-generated, human-governed. Something look off? Contact us to request a review.
Keep reading
Other papers Nabu has evaluated blind, starting with the same field.
Riedl, Farkas, Aygören-Pürsün, et al. · 2024 · Clinical medicine
Oral sebetralstat provided faster times to the beginning of symptom relief, reduction in attack severity, and complete attack resolution than placebo.
Well-supportedRiedl, Tachdjian, Lumry, et al. · 2024 · Clinical medicine
Donidalorsen at a dose of 80 mg administered subcutaneously every 4 or 8 weeks significantly reduced the hereditary angioedema attack rate
SupportedCohn, Gurugama, Magerl, et al. · 2024 · Clinical medicine
NTLA-2002 administered in a single dose of 25 mg or 50 mg reduced angioedema attacks and led to robust and sustained reduction in total plasma kallikrein levels in patients with hereditary angioedema.
Tentative